Drug Trial Radar · NCT03140969
Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Oct 16, 2017
Primary completion
Oct 2, 2019
Study completion Oct 2, 2019
Sponsor
- Lead sponsor
- Laboratoires TheaIndustry
- Sponsor type
- Industry
- Collaborators
- Sepul Bio
- First posted
- May 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of QR-110 administered via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
Conditions
- Leber's Congenital Amaurosis
Interventions
QR-110Drug
RNA antisense oligonucleotide for intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral EyesTime frame: 1 year
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa
Scheie Eye Institute, University of Pennsylvania
Philadelphia, Pennsylvania
Ghent University Hospital and Ghent University
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.